Home / Products / Monoclonal antibody /

Dynamin II Monoclonal Antibody

Product code: YP-Ab-00611
Promotional price:

Product introduction

Reactive species
Human
Applications
WB;IHC;IF;ELISA
Antibody type
Monoclonal antibodies
Gene Name
DNM2
Protein name
Dynamin-2
Dalton(DA)
Immunogen
Purified recombinant fragment of Dynamin II expressed in E. Coli.
Specificity
Dynamin II Monoclonal Antibody detects endogenous levels of Dynamin II protein.
Constitute
Ascitic fluid containing 0.03% sodium azide,0.5% BSA, 50%glycerol.
Source
Monoclonal, Mouse
Dilution rate
WB: 1/500 - 1/2000. IHC: 1/200 - 1/1000. ELISA: 1/10000.. IF 1:50-200
Purification process
Affinity purification
Concentration
Stockpile
-20°C/1 year
Other name
DNM2; DYN2; Dynamin-2
Background
dynamin 2(DNM2) Homo sapiens Dynamins represent one of the subfamilies of GTP-binding proteins. These proteins share considerable sequence similarity over the N-terminal portion of the molecule, which contains the GTPase domain. Dynamins are associated with microtubules. They have been implicated in cell processes such as endocytosis and cell motility, and in alterations of the membrane that accompany certain activities such as bone resorption by osteoclasts. Dynamins bind many proteins that bind actin and other cytoskeletal proteins. Dynamins can also self-assemble, a process that stimulates GTPase activity. Five alternatively spliced transcripts encoding different proteins have been described. Additional alternatively spliced transcripts may exist, but their full-length nature has not been determined. [provided by RefSeq, Jun 2010],
Function
catalytic activity:GTP + H(2)O = GDP + phosphate.,disease:Defects in DNM2 are a cause of centronuclear myopathy autosomal dominant (ADCNM) [MIM:160150]; also known as autosomal dominant myotubular myopathy. Centronuclear myopathies (CNMs) are congenital muscle disorders characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. CNMs comprise a wide spectrum of phenotypes, ranging from severe neonatal to mild late-onset familial forms. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and p

Open

Product Details

Customer data and reviews (0)

Fold content

Citation (0)

Fold content

Experimental scheme

Fold content
>